166 related articles for article (PubMed ID: 10845939)
1. Longitudinal monitoring of immune reconstitution by CDR3 size spectratyping after T-cell-depleted allogeneic bone marrow transplant and the effect of donor lymphocyte infusions on T-cell repertoire.
Verfuerth S; Peggs K; Vyas P; Barnett L; O'Reilly RJ; Mackinnon S
Blood; 2000 Jun; 95(12):3990-5. PubMed ID: 10845939
[TBL] [Abstract][Full Text] [Related]
2. Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism.
Wu CJ; Chillemi A; Alyea EP; Orsini E; Neuberg D; Soiffer RJ; Ritz J
Blood; 2000 Jan; 95(1):352-9. PubMed ID: 10607724
[TBL] [Abstract][Full Text] [Related]
3. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA
Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710
[TBL] [Abstract][Full Text] [Related]
4. Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion.
Sehn LH; Alyea EP; Weller E; Canning C; Lee S; Ritz J; Antin JH; Soiffer RJ
J Clin Oncol; 1999 Feb; 17(2):561-8. PubMed ID: 10080600
[TBL] [Abstract][Full Text] [Related]
5. Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion.
Claret EJ; Alyea EP; Orsini E; Pickett CC; Collins H; Wang Y; Neuberg D; Soiffer RJ; Ritz J
J Clin Invest; 1997 Aug; 100(4):855-66. PubMed ID: 9259585
[TBL] [Abstract][Full Text] [Related]
6. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation.
Giralt S; Hester J; Huh Y; Hirsch-Ginsberg C; Rondón G; Seong D; Lee M; Gajewski J; Van Besien K; Khouri I; Mehra R; Przepiorka D; Körbling M; Talpaz M; Kantarjian H; Fischer H; Deisseroth A; Champlin R
Blood; 1995 Dec; 86(11):4337-43. PubMed ID: 7492795
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
[TBL] [Abstract][Full Text] [Related]
8. T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect.
Alyea E; Weller E; Schlossman R; Canning C; Webb I; Doss D; Mauch P; Marcus K; Fisher D; Freeman A; Parikh B; Gribben J; Soiffer R; Ritz J; Anderson K
Blood; 2001 Aug; 98(4):934-9. PubMed ID: 11493435
[TBL] [Abstract][Full Text] [Related]
9. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia.
Hessner MJ; Endean DJ; Casper JT; Horowitz MM; Keever-Taylor CA; Roth M; Flomenberg N; Drobyski WR
Blood; 1995 Nov; 86(10):3987-96. PubMed ID: 7579370
[TBL] [Abstract][Full Text] [Related]
10. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation.
Bär BM; Schattenberg A; Mensink EJ; Geurts Van Kessel A; Smetsers TF; Knops GH; Linders EH; De Witte T
J Clin Oncol; 1993 Mar; 11(3):513-9. PubMed ID: 8445426
[TBL] [Abstract][Full Text] [Related]
11. In relapsed patients after lymphocyte depleted bone marrow transplantation the percentage of donor T lymphocytes correlates well with the outcome of donor leukocyte infusion.
Schattenberg A; Schaap N; Van De Wiel-Van Kemenade E; Bär B; Preijers F; Van Der Maazen R; Roovers E; De Witte T
Leuk Lymphoma; 1999 Jan; 32(3-4):317-25. PubMed ID: 10037029
[TBL] [Abstract][Full Text] [Related]
12. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
Pichert G; Roy DC; Gonin R; Alyea EP; Bélanger R; Gyger M; Perreault C; Bonny Y; Lerra I; Murray C
J Clin Oncol; 1995 Jul; 13(7):1704-13. PubMed ID: 7602361
[TBL] [Abstract][Full Text] [Related]
13. Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia.
Mackinnon S; Barnett L; Heller G
Bone Marrow Transplant; 1996 Apr; 17(4):643-7. PubMed ID: 8722369
[TBL] [Abstract][Full Text] [Related]
14. Identification of T-cell clones showing expansion associated with graft-vs-leukemia effect on chronic myelogenous leukemia in vivo and in vitro.
Kondo Y; Shiobara S; Nakao S
Exp Hematol; 2001 Apr; 29(4):471-6. PubMed ID: 11301187
[TBL] [Abstract][Full Text] [Related]
15. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
[TBL] [Abstract][Full Text] [Related]
16. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
[TBL] [Abstract][Full Text] [Related]
17. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.
Alyea EP; Soiffer RJ; Canning C; Neuberg D; Schlossman R; Pickett C; Collins H; Wang Y; Anderson KC; Ritz J
Blood; 1998 May; 91(10):3671-80. PubMed ID: 9573003
[TBL] [Abstract][Full Text] [Related]
18. Delayed recovery of CDR3 complexity of the T-cell receptor-beta chain in recipients of allogeneic bone marrow transplants who had virus-associated interstitial pneumonia: monitor of T-cell function by CDR3 spectratyping.
Hirokawa M; Horiuchi T; Kitabayashi A; Kawabata Y; Matsutani T; Suzuki R; Chihara J; Miura AB
J Allergy Clin Immunol; 2000 Jul; 106(1 Pt 2):S32-9. PubMed ID: 10887331
[TBL] [Abstract][Full Text] [Related]
19. Poor immune reconstitution after four or five major HLA antigens mismatched T cell-depleted allogeneic and autologous stem cell transplantation.
Mattsson J; Uzunel M; Remberger M; Tammik L; Omazic B; Levitsky V; Zou JZ; Hentschke P; Ringdén O
Clin Exp Immunol; 2001 Jan; 123(1):162-9. PubMed ID: 11168014
[TBL] [Abstract][Full Text] [Related]
20. Relationship between graft-versus-host disease and graft-versus-leukaemia in partial T cell-depleted bone marrow transplantation.
van der Straaten HM; Fijnheer R; Dekker AW; Nieuwenhuis HK; Verdonck LF
Br J Haematol; 2001 Jul; 114(1):31-5. PubMed ID: 11472341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
